Urine-Based Molecular Testing Service
University Hospitals of North Midlands NHS Trust
- Value
- Not stated
- Published
- 10 Sept 2026
- Deadline
- Not stated
- Procedure
- Not stated
- Location
- Stoke on Trent, UKG, ST4 6QG, United Kingdom
- Notice reference
- 086052-2026
Requirements summary
University Hospitals of North Midlands NHS Trust is procuring a urine-based molecular testing service to triage eligible non-visible haematuria patients as a non-invasive alternative to routine diagnostic cystoscopy for an agreed low-risk cohort. The provider must handle home sample collection and return logistics, laboratory analysis against a defined bladder cancer-associated molecular panel, and secure reporting of results as negative/low-risk or positive/high-risk. The amended estimated contract duration is 1 November 2026 to 31 March 2027.
Key requirements
- Provider of a urine-based molecular testing service for eligible non-visible haematuria patients
- Home urine sample collection, sample kits, return logistics and robust chain-of-custody
- Laboratory analysis against a defined bladder cancer-associated molecular panel with documented quality controls
- Results available within 7 calendar days of sample receipt, with at least 90% compliance; kits issued within 2 working days; non-conforming samples notified within 1 working day
- Service operates within UHNM clinical decision rules, including escalation routes and safety-netting for negative results
- Monthly KPI dashboard, quarterly clinical governance pack and support for pathway data collection
- Mobilisation within 4 weeks, followed by a 3-month pilot and business-as-usual delivery from month 4 where agreed